More on RUBY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (4.3 Score)

Upcoming Events

- Earnings (5/15/20 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Rubius Therapeutics (NQ:RUBY)
Delayed: 25.13 --0 (-0%)
Prev. Close $25.13  
Open$25.13 
52 Wk High$ 
52 Wk Low$ 
Day High$25.13 
Day Low$25.13 
P/E N/A  
EPS$ 
Volume1 

Friends, Peers and Foes (?): EVLO, KLDO, MRNA, DNLI, MCRB (more...)

Apr 26, 2021 08:00 AM Rubius Therapeutics to Announce First Quarter 2021 Financial Results
Apr 26, 2021 08:00 AM Rubius Therapeutics to Announce First Quarter 2021 Financial Results
Apr 12, 2021 08:07 AM Rubius Therapeutics (RUBY) Reports First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Apr 12, 2021 08:00 AM Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Apr 12, 2021 08:00 AM Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Apr 9, 2021 08:02 AM Rubius Therapeutics (RUBY) Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors
Apr 9, 2021 08:00 AM Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
Apr 9, 2021 08:00 AM Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meetin
Apr 7, 2021 07:00 AM Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
Mar 30, 2021 09:30 AM Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer
View All Articles